1
|
Sun N, Wang T, Zhang S. Radionuclide-labelled nanoparticles for cancer combination therapy: a review. J Nanobiotechnology 2024; 22:728. [PMID: 39578828 PMCID: PMC11585169 DOI: 10.1186/s12951-024-03020-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2024] [Accepted: 11/14/2024] [Indexed: 11/24/2024] Open
Abstract
Radionuclide therapy (RT) is widely used to advanced local cancers. However, its therapeutic efficacy is limited to the radiation resistance of cancer cells. Combination therapy aims to circumvent tumor resistance, and the combination of RT with photothermal therapy (PTT), photodynamic therapy (PDT), chemotherapy (CMT), and immunotherapy has shown promising treatment outcomes. Nanotechnology holds promise in advancing combination therapy by integrating multiple therapies on a nanostructure platform. This is due to the increased surface area, passive/active targeting capabilities, high payload capacity, and enriched surface of nanomedicines, offering significant advantages in treatment sensitivity and specificity. In the first part of this review, we categorize radionuclide therapy. The second part summarizes the latest developments in combination therapies, specifically focusing on the integration of RT with PTT, PDT, CMT and immunotherapy. The last part provides an overview of the challenges and potential opportunities related to radionuclide-labelled nanoparticles for cancer combination therapy.
Collapse
Affiliation(s)
- Na Sun
- Department of Nuclear Medicine, XinQiao Hospital, Army Medical University, ChongQing, 400037, China
| | - Tao Wang
- Department of Nuclear Medicine, XinQiao Hospital, Army Medical University, ChongQing, 400037, China
| | - Song Zhang
- Department of Nuclear Medicine, XinQiao Hospital, Army Medical University, ChongQing, 400037, China.
| |
Collapse
|
2
|
Preparation and quality control of a new porphyrin complex labeled with 45Ti for PET imaging. Appl Radiat Isot 2023; 193:110650. [PMID: 36646031 DOI: 10.1016/j.apradiso.2023.110650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 12/27/2022] [Accepted: 01/04/2023] [Indexed: 01/11/2023]
Abstract
This study aims to produce and quality control of a new porphyrin complex labeled with 45Ti for PET imaging, so at the first step, the cross-section of 45Sc(p,n)45Ti was investigated by TALYS-1.6 and the optimal target thickness and theoretical yield were calculated by SRIM code. The purified 45Ti was labeled with the anticancer agent of tetrakis (pentafluorophenyl) porphyrin (TFPP). The radiochemical purity and the percentage of labeling were evaluated by radiation layer chromatography then the division coefficient of [45Ti]-TFPP was calculated. The dual coincidence imaging system was used for imaging 1 and 2 h after injection [45Ti]-TFPP to rats. Immediately after imaging, the mean percent injected dose per gram and specific activity of different tissues including blood, heart, lungs, stomach, liver, bone, kidney, spleen, intestine, muscle, feces, and skin were measured. The yield of 45Ti production was measured 468 MBq/μAh and the labeling rate was observed more than 98%. The highest activity was observed in the liver (%ID/g = 2.27%, 1 h) and spleen (2.2%, 1 h), respectively, because of the high lipophilic of 45Ti-TFPP. SPECT images showed a significant uptake of radiopharmaceuticals in the abdomen. The labeling rate of 45Ti-TFPP was high and this compound has the potential for clinical application in different ways than PSMA, it can be joined with photodynamic therapy (Severin et al., 2015).
Collapse
|
3
|
Jin GQ, Chau CV, Arambula JF, Gao S, Sessler JL, Zhang JL. Lanthanide porphyrinoids as molecular theranostics. Chem Soc Rev 2022; 51:6177-6209. [PMID: 35792133 PMCID: PMC12005637 DOI: 10.1039/d2cs00275b] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
In recent years, lanthanide (Ln) porphyrinoids have received increasing attention as theranostics. Broadly speaking, the term 'theranostics' refers to agents designed to allow both disease diagnosis and therapeutic intervention. This Review summarises the history and the 'state-of-the-art' development of Ln porphyrinoids as theranostic agents. The emphasis is on the progress made within the past decade. Applications of Ln porphyrinoids in near-infrared (NIR, 650-1700 nm) fluorescence imaging (FL), magnetic resonance imaging (MRI), radiotherapy, and chemotherapy will be discussed. The use of Ln porphyrinoids as photo-activated agents ('phototheranostics') will also be highlighted in the context of three promising strategies for regulation of porphyrinic triplet energy dissipation pathways, namely: regioisomeric effects, metal regulation, and the use of expanded porphyrinoids. The goal of this Review is to showcase some of the ongoing efforts being made to optimise Ln porphyrinoids as theranostics and as phototheranostics, in order to provide a platform for understanding likely future developments in the area, including those associated with structure-based innovations, functional improvements, and emerging biological activation strategies.
Collapse
Affiliation(s)
- Guo-Qing Jin
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P. R. China.
| | - Calvin V Chau
- Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA.
| | - Jonathan F Arambula
- Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA.
- InnovoTEX, Inc. 3800 N. Lamar Blvd, Austin, Texas 78756, USA.
| | - Song Gao
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P. R. China.
- Chemistry and Chemical Engineering Guangdong Laboratory, Shantou 515031, P. R. China
- Guangdong-Hong Kong-Macao Joint Laboratory of Optoelectronic and Magnetic Functional Materials, Spin-X Institute, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P. R. China
| | - Jonathan L Sessler
- Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, USA.
| | - Jun-Long Zhang
- Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, P. R. China.
- Chemistry and Chemical Engineering Guangdong Laboratory, Shantou 515031, P. R. China
| |
Collapse
|
4
|
Ozada C, Tekin V, Barlas FB, Timur S, Unak P. Protoporphyrin‐IX and Manganese Oxide Nanoparticles Encapsulated in Niosomes as Theranostic. ChemistrySelect 2020. [DOI: 10.1002/slct.201901620] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Cagatay Ozada
- Department of Nuclear Applications, Institute of Nuclear Sciences Ege University 35100 Bornova Izmir Turkey
| | - Volkan Tekin
- Department of Nuclear Applications, Institute of Nuclear Sciences Ege University 35100 Bornova Izmir Turkey
| | - F. Baris Barlas
- Department of Biochemistry, Faculty of Science Ege University, Bornova, Izmir Turkey
| | - Suna Timur
- Department of Biochemistry, Faculty of Science Ege University, Bornova, Izmir Turkey
| | - Perihan Unak
- Department of Nuclear Applications, Institute of Nuclear Sciences Ege University 35100 Bornova Izmir Turkey
| |
Collapse
|
5
|
Fazaeli Y, Hosseini MA, Shahabinia F, Feizi S. 68Ga-5, 10, 15, 20-Tetrakis (2, 4, 6-trimethoxy phenyl) porphyrin: a novel radio-labeled porphyrin complex for positron emission tomography. J Radioanal Nucl Chem 2019. [DOI: 10.1007/s10967-019-06465-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
6
|
Noorin ES, Feizi S, Dehaghi SM. Dosimetric characterization of novel polycarbonate/porphyrin film dosimeters for high dose dosimetry: study on complexation effect. RADIOCHIM ACTA 2018. [DOI: 10.1515/ract-2017-2839] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Abstract
Two novel radiochromic films with 20 μm thickness were made from casting of solutions of polycarbonate (PC) containing 0.5 wt.% tetra phenyl porphyrin (TPPH2) and 5,10,15,20-tetraphenyl-21H,23H-porphine iron(III) chloride (Fe-TPP). Dosimetric characterization of the films as routine dosimeters were studied by spectrophotometric method. On subjecting TPPH2/PC and Fe-TPP/PC film dosimeters to gamma radiation, radiolytic bleaching of films was observed. The effects of metal-complexation on the radiation response of the film dosimeters were studied under 60Co γ-rays exposure in dose range of 0–100 kGy. The results were also compared with the PC/TPPF20 (PC/tetrakis (pentafluorophenyl) porphyrin) dosimeter to evaluate the substituent effect (role of fluorine groups). Experimental parameters including humidity, temperature and pre-irradiation (shelf-life) and post-irradiation storage in dark and in indirect sunlight were examined. The maximum absorbance of Soret band of dyes had meaningful shifts and reduction which arose from complexation and substituents. The dyed films characteristics were found to be stable enough in media with high degrees of temperature and humidity. The results indicate that the radiation-induced decoloration of TPPH2/PC and Fe-TPP/PC films can be reliably tuned and used in high dose dosimetry.
Collapse
|
7
|
Song H, Wang G, Wang J, Wang Y, Wei H, He J, Luo S. 131I-labeled 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin and 5,10,15,20-tetrakis(4-aminophenyl)porphyrin for combined photodynamic and radionuclide therapy. J Radioanal Nucl Chem 2018. [DOI: 10.1007/s10967-018-5735-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Jalilian AR, Beiki D, Hassanzadeh-Rad A, Eftekhari A, Geramifar P, Eftekhari M. Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran. Semin Nucl Med 2017; 46:340-58. [PMID: 27237443 DOI: 10.1053/j.semnuclmed.2016.01.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
During past 3 decades, nuclear medicine has flourished as vibrant and independent medical specialty in Iran. Since that time, more than 200 nuclear physicians have been trained and now practicing in nearly 158 centers throughout the country. In the same period, Tc-99m generators and variety of cold kits for conventional nuclear medicine were locally produced for the first time. Local production has continued to mature in robust manner while fulfilling international standards. To meet the ever-growing demand at the national level and with international achievements in mind, work for production of other Tc-99m-based peptides such as ubiquicidin, bombesin, octreotide, and more recently a kit formulation for Tc-99m TRODAT-1 for clinical use was introduced. Other than the Tehran Research Reactor, the oldest facility active in production of medical radioisotopes, there is one commercial and three hospital-based cyclotrons currently operational in the country. I-131 has been one of the oldest radioisotope produced in Iran and traditionally used for treatment of thyrotoxicosis and differentiated thyroid carcinoma. Since 2009, (131)I-meta-iodobenzylguanidine has been locally available for diagnostic applications. Gallium-67 citrate, thallium-201 thallous chloride, and Indium-111 in the form of DTPA and Oxine are among the early cyclotron-produced tracers available in Iran for about 2 decades. Rb-81/Kr-81m generator has been available for pulmonary ventilation studies since 1996. Experimental production of PET radiopharmaceuticals began in 1998. This work has culminated with development and optimization of the high-scale production line of (18)F-FDG shortly after installation of PET/CT scanner in 2012. In the field of therapy, other than the use of old timers such as I-131 and different forms of P-32, there has been quite a significant advancement in production and application of therapeutic radiopharmaceuticals in recent years. Application of (131)I-meta-iodobenzylguanidine for treatment of neuroblastoma, pheochromocytoma, and other neuroendocrine tumors has been steadily increasing in major academic university hospitals. Also (153)Sm-EDTMP, (177)Lu-EDTMP, (90)Y-citrate, (90)Y-hydroxyapatite colloid, (188/186)Re-sulfur colloid, and (188/186)Re-HEDP have been locally developed and now routinely available for bone pain palliation and radiosynovectomy. Cu-64 has been available to the nuclear medicine community for some time. With recent reports in diagnostic and therapeutic applications of this agent especially in the field of oncology, we anticipate an expansion in production and availability. The initiation of the production line for gallium-68 generator is one of the latest exciting developments. We are proud that Iran would be joining the club of few nations with production lines for this type of generator. There are also quite a number of SPECT and PET tracers at research and preclinical stage of development preliminarily introduced for possible future clinical applications. Availability of fluorine-18 tracers and gallium-68 generators would no doubt allow rapid dissemination of PET/CT practices in various parts of our large country even far from a cyclotron facility. Also, local production and availability of therapeutic radiopharmaceuticals are going to open exciting horizons in the field of nuclear medicine therapy. Given the available manpower, local infrastructure of SPECT imaging, and rapidly growing population, the production of Tc-99m generators and cold kit would continue to flourish in Iran.
Collapse
Affiliation(s)
| | - Davood Beiki
- Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Arman Hassanzadeh-Rad
- Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Arash Eftekhari
- Diagnostic Radiology/Nuclear Medicine, Surrey Memorial Hospital and Jim Pattison Outpatient Care and Surgery Centre, Surrey, British Columbia, Canada
| | - Parham Geramifar
- Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Eftekhari
- Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
9
|
Abedi M, Nabid MR, Shirvani-Arani S, Bahrami-Samani A, Vahidfar N. Preparation and biological evaluation of a carrier free 90yttrium labelled porphyrin as a possible agent for targeted therapy of tumor. J PORPHYR PHTHALOCYA 2017. [DOI: 10.1142/s1088424617300038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
In this research article, 5,10,15,20-tetrakis(phenyl)porphyrin (H2TPP) was produced and characterized. Then, radiolabeling of H2TPP was performed using the carrier free Y-90 which was prepared by the use of a home-made yttrium imprinted sorbent. The radiolabeling procedure was accomplished at 60 [Formula: see text] C during 12 h with a suitable radiochemical purity (95 ± 2% ITLC, 99 ± 0.5% HPLC) and specific activity of (1.0 ± 0.1 GBq/mmol). The obtained radio-labeled H2TPP in final formulation was kept for a week in order to investigate the complex stability. Accordingly, the partition coefficient was calculated as log [Formula: see text] 2.05. Furthermore, the biodistribution of the [Formula: see text]Y–TPP was determined in vital organs of normal wild-type rats using scarification studies. The kidneys could mostly remove the radio-complexes from the blood circulation and in less extends from the liver. As a result it is expected that due to its lipophilicity the higher mitochondrial and thus, tumor cell uptake of this radiolabeled porphyrin happens and therefore [Formula: see text]Y–TPP could act as an efficient potential agent for targeted therapy of tumor.
Collapse
Affiliation(s)
- Mahvash Abedi
- Department of polymer, Faculty of Chemistry, Shahid Beheshti University, G. C., 1983963113, Tehran, Iran
- Nuclear Science and Technology Research Institute (NSTRI), P.O. Box: 11365-8486, Tehran, Iran
| | - Mohammad Reza Nabid
- Department of polymer, Faculty of Chemistry, Shahid Beheshti University, G. C., 1983963113, Tehran, Iran
| | | | - Ali Bahrami-Samani
- Nuclear Science and Technology Research Institute (NSTRI), P.O. Box: 11365-8486, Tehran, Iran
| | - Nasim Vahidfar
- Nuclear Science and Technology Research Institute (NSTRI), P.O. Box: 11365-8486, Tehran, Iran
| |
Collapse
|
10
|
Fazaeli Y, Feizi S, Jalilian AR, Hejrani A. Grafting of [64Cu]-TPPF20 porphyrin complex on Functionalized nano-porous MCM-41 silica as a potential cancer imaging agent. Appl Radiat Isot 2016; 112:13-9. [DOI: 10.1016/j.apradiso.2016.03.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2015] [Revised: 02/15/2016] [Accepted: 03/03/2016] [Indexed: 12/19/2022]
|
11
|
Fazaeli Y, Jalilian AR, Rezaee F, Firouzyar T, Moradkhani S, Bagheri A, Majdabadi A. Development of radiolabeled radachlorin complex as a possible tumor targeting agent. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3645-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
12
|
Fakhari A, Jalilian AR, Yousefnia H, Johari-Daha F, Mazidi M, Khalaj A. Development of 166Ho-pamidronate for bone pain palliation therapy. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3515-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|